

R46-A

Polar Capital Funds PLC - Biotechnology Fund



Global developed and emerging market equities focusing on biotechnology related stocks. Active fundamental stock selection approach.

Über den Fonds

Daten zum May 30th 2026

Polar Capital is a UK-based investment-led boutique fund manager founded in 2001. It manages over \$40bn of AUM through 13 autonomous investment teams managing specialist, active and capacity constrained portfolio.


The **Polar Biotechnology Fund** is an actively managed fund that aims to preserve capital and achieve long-term capital appreciation by investing throughout the biotechnology ecosystem, across geographies and market capitalisations. The fund looks to invest in cutting-edge medical innovation where the stock market is under-appreciating a company's potential to transform medical practice should one of its new drugs, devices or research tools be successfully developed and commercialised. The fund therefore approaches investing based on industry and company fundamentals, and more specifically seeking to identify specific catalysts for a change in the perceived value of an asset or technology platform - these catalysts can come in the form of clinical data, regulatory decisions, partnering deals between companies, or quarterly-reported sales of commercialised assets. The fund typically has a concentrated portfolio of 40-60 holdings.

Polar Capital Funds PLC - Biotechnology Fund

Anlagestil	Actively managed
Anlageklasse	<u>Global equities - healthcare</u> <u>focused</u>
Max. empfohlener Portfolioanteil	10%
ISIN	IE00B4ZZ4531
Anteilklass	I Dis USD
Ausschüttung	—
TER	1.10% p.a.
Nachhaltigkeit (SFDR)	Article 8

Wertentwicklung

Preisentwicklung – Maximaler Zeitraum



Bausteinrenditen

Polar Capital Funds PLC - Biotechnology Fund

Ann. Rendite (3 J.):	23.39%
Ann. Rendite (5 J.):	11.91%
Ann. Rendite (10 J.):	16.15%
Ann. Standardabweichung (5 J.):	19.54%
This fund represents active exposure to global biotechnology-related companies that is a sub-theme or sub-sector of healthcare.	

Benchmark-Renditen

SPDR MSCI All Country World UCITS ETF

Ann. Rendite (3 J.):	22.50%
Ann. Rendite (5 J.):	11.44%
Ann. Rendite (10 J.):	12.76%
Ann. Standardabweichung (5 J.):	14.46%

↗ [Link zum Fonds-FairSheet](#)

FairHorizont-Benchmark-Renditen

Dimensional Funds PLC - World Equity Fund


Ann. Rendite (3 J.):	20.42%
Ann. Rendite (5 J.):	9.89%
Ann. Rendite (10 J.):	—
Ann. Standardabweichung (5 J.):	15.01%

↗ [Link zum Fonds-FairSheet](#)

The **Dimensional World Equity Fund** is our **FAIRHORIZON Red** reference benchmark solution that has primarily global developed equities for long-term global equity-like returns and volatility.

Das FairHorizont-Konzept

Anlagezeithorizont in Jahren



Erwartete Langfristrendite	2 - 4% p.a.
Erwartete Volatilität	3 - 5% p.a.

Warum wir diesen Fonds bevorzugen


Relevance of strategy

This fund represents active exposure to global biotechnology-related companies that is a sub-theme or sub-sector of healthcare.

Differentiated portfolio

The fund runs a fundamental stock selection approach with a focus on identifying catalysts for a change in the perceived value of the stocks.

Historischer maximaler Drawdown & Erholungszeit



Max. Drawdown (seit Auflage)	-35.42%
Erholungsperiode	567 Tage

Diversifizierung




Top 10 Positionen

Arcutis Biotherapeutics Inc	5.66%
Revolution Medicines Inc	5.62%
Madrigal Pharmaceuticals Inc	5.51%
Argenx SE	5.31%
Regeneron Pharmaceuticals Inc	4.87%
Rhythm Pharmaceuticals Inc	4.45%
UCB SA Ordinary Shares	4.32%
Bridgebio Pharma Inc	3.48%
Newamsterdam Pharma Co NV	3.42%
Alnylam Pharmaceuticals Inc	3.36%



Sektoren

Health Care	95.06%
Cash	1.91%
Others	3.03%



Geographie

U.S.A.	70.75%
Netherlands	8.67%
Belgium	4.17%
United Kingdom	3.46%
Denmark	2.97%
Canada	2.29%
Cash	1.91%
Sweden	1.85%
France	0.90%
Others	3.03%

Gefällt Ihnen dieser Fonds? Sprechen Sie mit uns!

Möchten Sie mehr über diese Investitionslösung oder über uns erfahren?

MIT UNSEREM RESEARCH-TEAM SPRECHEN



Mario Becker
CEO & Gründer



Lim Chuin Hao
Leiter Research
ch@dfo.sg

